New research on the financial practices surrounding a ‘wonder drug’ with a more than 90 percent cure rate for hepatitis C—a blood-borne infection that damages the liver over many years—shows how this medical breakthrough, developed with the help of public funding, was acquired by a major pharmaceutical company following a late-stage bidding war. The research…